LEADER 03789nam 2200733Ia 450 001 9910792029003321 005 20200520144314.0 010 $a0-8047-8657-7 024 7 $a10.1515/9780804786577 035 $a(CKB)2560000000101867 035 $a(SSID)ssj0000918466 035 $a(PQKBManifestationID)11541702 035 $a(PQKBTitleCode)TC0000918466 035 $a(PQKBWorkID)10895390 035 $a(PQKB)10036840 035 $a(MiAaPQ)EBC1191536 035 $a(DE-B1597)563694 035 $a(DE-B1597)9780804786577 035 $a(Au-PeEL)EBL1191536 035 $a(CaPaEBR)ebr10704775 035 $a(OCoLC)846551598 035 $a(OCoLC)1198930135 035 $a(PPN)236069934 035 $a(EXLCZ)992560000000101867 100 $a20121026d2013 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aOf medicines and markets$b[electronic resource] $eintellectual property and human rights in the free trade era /$fAngelina Snodgrass Godoy 210 $aStanford, California $cStanford University Press$dc2013 215 $axiv, 183 p. $cill 225 1 $aStanford studies in human rights 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a0-8047-8560-0 311 $a0-8047-8561-9 320 $aIncludes bibliographical references and index. 327 $tFrontmatter -- $tContents -- $tForeword -- $tAcronyms and Abbreviations -- $tAcknowledgments -- $t1. Trading Health for Wealth -- $t2. A Primer on Pharmaceutical Intellectual Property -- $t3. Market Failures and Fallacies -- $t4. Local Politics, Strange Bedfellows, and the Challenges of Human Rights Mobilization -- $t5. Patient Advocacy and Access to Medicines Litigation -- $t6. Writing Globalization?s Rule Book -- $tNotes -- $tReferences -- $tIndex 330 $aCentral American countries have long defined health as a human right. But in recent years regional trade agreements have ushered in aggressive intellectual property reforms, undermining this conception. Questions of IP and health provisions are pivotal to both human rights advocacy and "free" trade policy, and as this book chronicles, complex political battles have developed across the region. Looking at events in Costa Rica, El Salvador, and Guatemala, Angelina Godoy argues that human rights advocates need to approach intellectual property law as more than simply a roster of regulations. IP represents the cutting edge of a global tendency to value all things in market terms: Life forms?from plants to human genetic sequences?are rendered commodities, and substances necessary to sustain life?medicines?are restricted to insure corporate profits. If we argue only over the terms of IP protection without confronting the underlying logic governing our trade agreements, then human rights advocates will lose even when they win. 410 0$aStanford studies in human rights. 606 $aDrug accessibility$zCentral America 606 $aDrugs$xPatents 606 $aFree trade$zCentral America 606 $aHuman rights$zCentral America 606 $aIntellectual property$zCentral America 606 $aPharmaceutical policy$zCentral America 606 $aRight to health$zCentral America 615 0$aDrug accessibility 615 0$aDrugs$xPatents. 615 0$aFree trade 615 0$aHuman rights 615 0$aIntellectual property 615 0$aPharmaceutical policy 615 0$aRight to health 676 $a338.4/7615109728 700 $aGodoy$b Angelina Snodgrass$01570992 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910792029003321 996 $aOf medicines and markets$93845031 997 $aUNINA